Pseudomembranous Colitis Clinical Trial
Official title:
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Verified date | May 2017 |
Source | VA Medical Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
Status | Completed |
Enrollment | 22 |
Est. completion date | January 2007 |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient must be > 18 years of age - Clinical diagnosis of C. difficile associated disease, based on the new onset of diarrhea, abdominal discomfort, or otherwise unexplained fever or leukocytosis - Diagnosis of C. difficile colitis proven by positive assay for C. difficile toxin in feces - Disease has been treated, and the symptoms failed to respond to treatment with metronidazole or vancomycin, or symptoms promptly relapsed after completing a course of therapy with either of these drugs - Able to take oral medication Exclusion Criteria: - Patients with other recognized causes of diarrhea or colitis - Women of child bearing age who are pregnant, breast feeding, or not using birth control - Patients taking coumadin, phenytoin, celecoxib, or losartan - Patients with renal insufficiency (BUN or creatinine >2 times baseline) - Serious systemic disorder incompatible with the study |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine | Houston | Texas |
United States | Michael E. Debakey VA Medical Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Daniel M. Musher MD | Baylor College of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nitazoxanide | stopping of diarrhea | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00382304 -
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
|
Phase 2 | |
Completed |
NCT00304876 -
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
|
N/A | |
Completed |
NCT03427229 -
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
|
Phase 2 | |
Completed |
NCT00106509 -
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
|
Phase 3 | |
Completed |
NCT00304369 -
Response of Clostridium Difficile Infection to Metronidazole Therapy
|
N/A | |
Completed |
NCT00304889 -
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
|
Phase 3 | |
Completed |
NCT00304408 -
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
|
Phase 4 | |
Completed |
NCT00182429 -
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
|
Phase 3 | |
Withdrawn |
NCT00304863 -
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
|
Phase 4 |